Our Mission
To develop breakthrough treatments for neurodegenerative diseases utilizing innovative drugs to improve neuroplasticity
To develop breakthrough treatments for neurodegenerative diseases utilizing innovative drugs to improve neuroplasticity
Enhancing positive neurological changes to fight neurodegeneration
New medications to prevent and treat neuropsychiatric disorders
Class-leading oral drugs to provide widely available treatment solutions
Zylorion aims to make major impacts across a wide range of hard-to-treat brain diseases. Building on increasing scientific knowledge over the past 40 years, we have successfully developed and patented novel compounds to address these. We are planning on commencing clinical trials with the aim of developing safe and effective drugs which can potentially transform the treatment of multiple diseases and disorders of the CNS (central nervous system).
Zylorion was founded to expand upon research demonstrating a potential role for novel neuroplasticity drugs
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
Zylorion was founded to expand upon research demonstrating a potential role for novel neuroplasticity drugs
Successfully raised the first round of funding and current leadership and board teams were recruited
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
Successfully raised the first round of funding and current leadership and board teams were recruited
First development of what would become ZYL-314 in collaboration with our international manufacturing partners
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
First development of what would become ZYL-314 in collaboration with our international manufacturing partners
Our research demonstrated the unique novel capabilities of ZYL-314 and the first patent was awarded for this new chemical entity
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
Our research demonstrated the unique novel capabilities of ZYL-314 and the first patent was awarded for this new chemical entity
Our research demonstrated additional ways in which ZYL-314 positively enhances BDNF / TrkB activation in multiple preclinical models
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
Our research demonstrated additional ways in which ZYL-314 positively enhances BDNF / TrkB activation in multiple preclinical models
We aim to start testing our lead compound in humans in 2025, following interactions with appropriate regulatory authorities
Our research demonstrated additional ways in which ZYL-314 positively enhancesBDNF / TrkB activation in multiple preclinical models
We aim to start testing our lead compound in humans in 2025, following interactions with appropriate regulatory authorities
.webp)
